Analyst consensus rating
Lexaria Bioscience Analyst Rating: none
LEXX is rated none by 2 analysts with a $52.50 target. As of 2026-08-31.
Direct answer
Lexaria Bioscience's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $52.50.
Forecast evidence checked August 31, 2026.
Get free Lexaria Bioscience email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.35
- Average price target
- $52.50
- High price target
- $82.50
- Low price target
- $22.50
- Low target gap
- +117.4%
- Target upside
- +407.2%
- High target gap
- +697.1%
- Target range width
- 579.7%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lexaria Bioscience?
Lexaria Bioscience has a verified none consensus. The same dataset has an average price target of $52.50.
How far are Lexaria Bioscience's low and high targets from the recorded price?
The low target implies +117.4%, while the high target implies +697.1%.
How many analysts are included in Lexaria Bioscience's consensus?
The verified consensus includes 2 analysts.
How is Lexaria Bioscience's target upside or downside calculated?
The average target of $52.50 is divided by the recorded price of $10.35, then one is subtracted to produce +407.2%. This does not guarantee a future return.
When was Lexaria Bioscience's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.